Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Using Predictive Models to Reduce Heterogeneity in Alzheimer’s Disease Clinical Trials

              Author:Ezzati, Ali   Petersen, Kellen   Nallapu, Bhargav   Lipton, Richard   

              Session Name:S26: Experimental Therapeutics in Dementia  

              Topic:Aging and Dementia  

              Program Number:S26.005  

              Author Institution:Albert Einstein College of Medicine, Great neck, NY  Albert Einstein College of Medicine, Bronx, NY  

              Zavegepant 10 mg Nasal Spray is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials

              Author:Pavlovic, Jelena   Smith, Timothy   Mullin, Kathleen   Joshi, Shivang   Croop, Robert   Madonia, Jennifer   Mosher, Linda   Lovegren, Meghan   Forshaw, Micaela   Lipton, Richard   

              Session Name:S47: Advances in Migraine Therapeutics  

              Topic:Headache  

              Program Number:S47.003  

              Author Institution:Albert Einstein College of Medicine, Bronx, NY  StudyMetrix Research, Saint Louis, MO  New England Institute for Neurology and Headache, Stamford, CT  Community Neuroscience Services, Westborough, MA  Biohaven Pharmaceuticals, Wynnewood, PA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Wallingford, CT  

              Zavegepant Nasal Spray for the Acute Treatment of Migraine With Aura and Without Aura: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials

              Author:Smith, Timothy   Pavlovic, Jelena   Mullin, Kathleen   Joshi, Shivang   Croop, Robert   Madonia, Jennifer   Mosher, Linda   Lovegren, Meghan   Forshaw, Micaela   Lipton, Richard   

              Session Name:S47: Advances in Migraine Therapeutics  

              Topic:Headache  

              Program Number:S47.004  

              Author Institution:StudyMetrix Research, Saint Louis, MO  Albert Einstein College of Medicine, Bronx, NY  New England Institute for Neurology and Headache, Stamford, CT  Community Neuroscience Services, Westborough, MA  Biohaven Pharmaceuticals, Wynnewood, PA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Wallingford, CT  

              Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial

              Author:Pozo-Rosich, Patricia   Ailani, Jessica   Ashina, Messoud   Goadsby, Peter   Lipton, Richard   Reuter, Uwe   Guo, Hua   Schwefel, Brittany   Boinpally, Ramesh   McCusker, Emily   Yu, Sung Yun   Finnegan, Michelle   Trugman, Joel   

              Session Name:S47: Advances in Migraine Therapeutics  

              Topic:Headache  

              Program Number:S47.005  

              Author Institution:Vall d’Hebron University Hospital & Vall d’Hebron Institute of Research, Universitat Autonoma of Barcelona, Barcelona, Spain  Georgetown Headache Center, Georgetown University Hospital, McLean, VA  Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Glostrup, Denmark  NIHR-Wellcome Trust King's Clinical Research Facility, King's College London & University of California, Los Angeles, CA  Albert Einstein College of Medicine, Bronx, NY  Department of Neurology, Charité-Universitätsmedizin Berlin & Universitätsmedizin Greifswald, Berlin, Germany  AbbVie, Madison, NJ  AbbVie, North Chicago, IL  AbbVie, Madison , NJ  

              Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial

              Author:Mullin, Kathleen   Croop, Robert   Pavlovic, Jelena   Mosher, Linda   Smith, Timothy   Madonia, Jennifer   Lovegren, Meghan   Lipton, Richard   

              Session Name:PL5: Clinical Trials Plenary Session  

              Topic:Headache  

              Program Number:PL5.002  

              Author Institution:New England Institute for Neurology and Headache, Stamford, CT  Biohaven Pharmaceuticals, Wynnewood, PA  Albert Einstein College of Medicine, Bronx, NY  Biohaven Pharmaceuticals, Wallingford, CT  StudyMetrix Research, St Louis, MO  Biohaven Pharmaceuticals, New Haven, CT